Progress in the definition of the roles of various costimulators and cytokines in determining the type and height of immune responses has made it important to explore genetically altered tumor cells expressing such molecules for therapeutic immunizations. We have studied the effect of therapeutic subcutaneous (s.c.) immunizations on the growth of preexisting intracerebral brain tumor isografts in the rat. Transfectant glioma cell clones expressing either rat interferon-␥ (IFN-␥), rat interleukin-7 (IL-7), or rat B7-1 were selected. After irradiation (80 Gy) the clones were used for immunization (administered in up to four s.c. doses in a hind leg over 14-day intervals starting 1 day after the intracranial isografting of the parental tumor). Significant growth inhibition of the intracerebral parental tumors was induced by transfectants expressing IFN-␥ and IL-7, respectively. The strongest effect was observed with IFN-␥-expressing cells, resulting in cures in 37% of the males and in 100% of the females. Immunization with IL-7 had a similar, strong initial effect, with significantly prolonged survival in the majority of the rats but a lower final cure rate (survival for Ͼ150 days). The B7-1-expressing tumor clones induced cures in seven of eight female rats; however, no cures were seen in the male rats. It was also shown that the B7-1-expressing cells were themselves strongly immunogenic in female rats, requiring high cell numbers to result in a progressively growing tumor upon s.c. isografting; this was not the case in male rats. As a whole, the results imply that despite the unfavorable location of intracerebral tumors, therapeutic s.c. immunizations with certain types of genetically altered tumor cells can induce complete regressions with permanent survival and without gross neurological or other apparent signs of brain damage. The present results demonstrate complete regressions when immunizations are initiated shortly after intracranial isografting, when the intracerebral tumor is small. therapeutic immunizations (i.e., initiating the immunization when the "challenge tumor" is already established), it is important to keep in mind that the induced immunity is intended to eliminate even higher cell numbers under conditions when tumors have already established their stromal organization and blood supply. For many tumors, the major obstacle for successful immunotherapy does not seem to be a lack of expression of target Ags or an absence of responding lymphocytes, but rather that the immune response is quantitatively and/or qualitatively insufficient to eliminate the required number of tumor cells. A well-recognized reason for weak tumor immunogenicity is that tumor cells frequently have a decreased expression of major histocompatibility complex (MHC) class I. 1,2 However, a much lower concentration of MHC class I seems to be required to make tumor cells sensitive to already activated, cytolytic effector cells.
M ost tumors seem to express tumor antigens (Ags) recognized by T cells, as demonstrated by various in vitro assays. With most experimental tumors, preimmunization with irradiated viable tumor cells can induce immunity to subsequent tumor isografts. This immunity to tumor isografts varies greatly in strength. Even when it is quite strong, it is often possible to overcome immunity by challenge with a larger number of tumor cells, in the range of 1-10 ϫ 10 6 cells. When considering therapeutic immunizations (i.e., initiating the immunization when the "challenge tumor" is already established), it is important to keep in mind that the induced immunity is intended to eliminate even higher cell numbers under conditions when tumors have already established their stromal organization and blood supply. For many tumors, the major obstacle for successful immunotherapy does not seem to be a lack of expression of target Ags or an absence of responding lymphocytes, but rather that the immune response is quantitatively and/or qualitatively insufficient to eliminate the required number of tumor cells. A well-recognized reason for weak tumor immunogenicity is that tumor cells frequently have a decreased expression of major histocompatibility complex (MHC) class I. 1, 2 However, a much lower concentration of MHC class I seems to be required to make tumor cells sensitive to already activated, cytolytic effector cells. 3 To achieve therapeutic efficiency, there is a great demand for various techniques to boost the generation of cytolytic immune effector cells.
Recent progress in the understanding of the role of various costimulators and cytokines in determining the type and height of immune responses has made it possible to exploit the use of transfectant tumor cells expressing such molecules for immunization. 4 -7 Expression of the costimulators B7-1 and B7-2 greatly increases tumor immunogenicity, and subsequent augmented immunity has also been demonstrated to the parental, nonmanipulated tumor. 8, 9 Similarly, tumor cells expressing certain transfected cytokine genes, including granulocyte-macrophage colony-stimulating factor, interleukin-2 (IL-2), IL-7, IL-12, and interferon-␥ (IFN-␥) have been demonstrated to induce immunity to subsequent challenge with the wild-type (wt) tumor. 10 -15 In the present investigation, we have studied the effect of therapeutic subcutaneous (s.c.) immunizations on the intracerebral growth of brain tumor isografts in rats. The tumor that was selected as a model had only a low expression of MHC class I and was only weakly immunogenic. With this type of tumor, one also has to face additional problems common to tumors located in the central nervous system. These tumors generally release immunosuppressive molecules; 16 the intracerebral responses can be restricted by the partial exclusion of immune effector cells by the blood-brain barrier, [17] [18] [19] and if a strong response is successfully achieved, it may be potentially hazardous because of damaging effects on normal cells of the central nervous system. 20, 21 However, some cases of brain tumor regression after immunotherapy have been reported previously. [22] [23] [24] [25] In the present investigation, we have cloned the rat genes for IFN-␥, IL-7, and B7-1, which were chosen for their ability to stimulate different stages of the pathway for cytotoxic T lymphocyte (CTL) activation; after transfection and selection of high expresser clones, we have investigated whether a regression of pre-existing intracerebral tumors can be reproducibly induced by s.c. immunization with these clones.
MATERIALS AND METHODS

Cells and reagents
The rat glioma cell line N32 was induced by ethyl-N-nitrosourea in vivo, 26 cultured in vitro, and cloned by limiting dilution. After cloning, the cells were frozen in a stock of several ampules in liquid nitrogen. For experimental use, cells were thawed from this stock and were never cultured for Ͼ4 months. The cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM Lglutamine, 10 mM hydroxyethylpiperazine ethane, 0.5 mM pyruvate, and 0.096% NaHCO 3 (RPMI-FCS). FCS was replaced with 1.5% syngeneic Fisher serum (RPMI-RS) for in vivo challenge and immunizations. For the selection of transfected cells, 400 g/mL geneticin (Life Technologies, Paisley, U.K.) was also supplemented.
The N32 cell line expresses transforming growth factor-␤ (TGF-␤) (15 ng/10 6 cells). Supernatant was tested by enzymelinked immunosorbent assay (ELISA) after 3 days of growth of 0.33 ϫ 10 6 cells in 1 mL of medium.
Animals
Rats of the inbred strain Fisher 344 were used. They were bred in our own breeding facilities by continuous brother-sister mating and were kept in a temperature-controlled environment. All animal procedures are in agreement with the rules of the Swedish Board of Animal Research.
Cloning and sequencing of the rat genes
The cloning and sequencing of the rat genes for IFN-␥, IL-7, and B7-1 are described elsewhere.* The GenBank accession numbers for the genes are as follows: IFN-␥, no. AF010466; IL-7, no. AF010465; and B7-1, no. AF010465.
Transfection and infection
The three different rat genes were inserted into the cloning site (either the BamHI or the EcoRI sites) of the retroviral vector pLXSN (GenBank accession no. M28248). This vector expresses the cloned gene from a murine leukemia virus-like long terminal repeat, whereas the neo gene for drug selection is driven by an internal simian virus 40 promoter. The gene constructs were sequenced, and 5 g of plasmid DNA was subsequently used to transfect the retroviral packaging cell line GPϩE86. 27 For transfection, we used Transfectam (Promega, Madison, Wis) according to the protocol of the manufacturer. After selection, cell colonies were selected that produced the highest number of retroviral particles. Supernatants of these cells were used to infect the tumor cells. The infected tumor cells were cultured on selective media (geneticin), and several single-cell clones were selected by limiting dilutions. The clones were checked for expression by either Northern blot analysis or semiquantitative polymerase chain reaction. This expression was later verified by other methods studying the expression of the protein (see below).
Transfectants of N32 selected on geneticin release geneticin for several days
The inhibitory effects of geneticin on lymphocyte stimulation in mixed lymphocyte-tumor culture can still be seen after 3 days, but not after 7 days of culture with geneticin-free medium (data not shown).
IFN and IL-7 assays
Tumor cells were plated (1 ϫ 10 5 cells/well in 1 mL of medium) in 48-well plates (Nunc, Roskilde, Denmark). The plates were incubated for 48 hours at 37°C, and supernatants were harvested. IFN-␥ expression was evaluated by ELISA (Biosource, Wetlake Village, Calif). For IL-7 expression, a bioassay was used: A total of 5 ϫ 10 5 syngeneic thymocytes were stimulated by a suboptimal dose of concanavalin A (Con A) (0.6 g/mL) plus sample supernatants or IL-7 standard (recombinant murine IL-7, Genzyme, Cambridge, Mass). After incubation for 48 hours at 37°C, the plates were incubated with [ 3 H]thymidine for another 6 hours; cell incorporation was measured in a beta-counter (1450 Microbeta, Wallac, Turku, Finland).
Cytofluorometry
The B7-transfected N32 cell clones were stained with CTLassociated Ag-4 (CTLA4)-immunoglobulin (Ig) (a generous gift of Dr. P.L. Linsley, Bristol-Meyers Squibb Pharmaceutical Research Institute, Seattle, Wash), which is a fusion protein of the extracellular domain of mouse CTLA4 with the constant domain of human IgG1, 28 as a first reagent and with antihuman IgG F c as a second reagent. Parental N32 glioma cells and IFN-␥-transfected cell clones were stained with Ox18-F for MHC class I or with Ox17-F (PharMingen, San Diego, Calif) for MHC class II. The samples were analyzed on a fluorescence-activated cell sorter (Becton Dickinson, San Jose, Calif).
Intracerebral isograft inoculation
For intracerebral experiments, parental N32 glioma cells (1 ϫ 10 4 cells/5 L) were inoculated into the brain in the right nucleus caudatus using a small stereotactic frame (Kopf, Tujunga, Calif). Coordinates were 2 mm to the right and in front of the bregma, and 5 mm deep as measured from the outer surface of the skull. The animals were sedated with 0.6 mL/100 g body weight (females), 0.53 mL/100 g (males Ͻ340 g), or 0.55 mL/100 g (males Ͼ340 g) Ketalar/Rompun. Cells were injected slowly for 2 minutes to diminish backflow through the insertion canal. The cannula was withdrawn with a 2-minute delay, and the hole in the skull was closed with bone wax.
For s.c. immunizations, cells were cultured free of G418 for 1 week, washed twice, and suspended in RPMI-RS; 0.2 mL was injected s.c. in the right thigh. In some immunizations, cells were diluted in 0.4 mL, and 0.2 mL was injected in both the right thigh and the dorsal part of the neck.
All rats receiving intracranial tumor inoculations were checked for macroscopically visible intracerebral tumors when killed with neurological symptoms or at the end of the experiment (Ͼ150 days). In some cases, including all rats that could not be judged macroscopically, whole brains were fixed and sectioned at three levels for histopathological evaluation as illustrated in Figure 1 .
Statistical analysis of survival
For statistical analysis, we used the Kaplan-Meier survival test with the Mantel-Cox log rank test (Statview 4.0, Abacus Concepts, Berkeley, Calif) to estimate a P value.
RESULTS
Intracerebral dose titration of N32-wt glioma isografts
Rats were inoculated intracerebrally with 500 -30,000 glioma cells (Fig 2) . All rats in all groups died within 3 weeks for the highest dose, and within 14 weeks for the lowest dose. There were no differences between male and female rats. Also, no rats in groups in which medium was administered as a therapy control survived in any of the experiments performed (data not shown).
Stability of expression of transfected genes in selected cell clones
After cell cloning, IFN-␥ production was confirmed by ELISA. Supernatants from 2-day cell cultures of 1 ϫ 10 5 cells/mL were assayed and compared with supernatants of parental N32 that expressed no IFN-␥. A high IFN-␥-producing clone was selected for further experiments and was retested after experimental use, at 4 months after thawing (Fig 3A) . This clone not only maintained most of its expression of IFN-␥ but also obtained an up-regulation of originally very weak MHC class I expression. The clone also displayed novel, high MHC class II expression, which is in contrast to a complete lack of expression in the parental tumor cells (Fig 3B) . No similar enhancement of MHC class I and/or II could be detected in the IL-7-or B7-1-transduced cells (data not shown).
IL-7 expression was analyzed after cloning and after experimental use (3 months after each thawing) by a functional assay measuring the rat thymocyte proliferation induced by a suboptimal dose of Con A and culture medium from selected clones or the original N32 (Fig 4) . B7-1 expression was analyzed with a fluorescenceactivated cell sorter using CTLA4-Ig and anti-human Ig F c -fluorescein isothiocyanate as reagents. Clone 13 expressed B7-1 stably, as confirmed after Ͼ6 weeks of culture without selective media (Fig 5) . The transfected cell clone showed 98% B7 ϩ cells (gate M1). Gate M1 was placed to give Ͻ0.5% positive cells by background labeling. Intracerebral growth of parental N32 gliomas isografted at various cell numbers. Each group consisted of both male and female rats (10 animals/group for the two highest doses and 6 animals/group for the three lowest doses). No differences in tumor growth between the sexes were observed.
VISSE, SIESJÖ , WIDEGREN, ET AL: BRAIN TUMOR REGRESSION AFTER THERAPEUTIC IMMUNIZATION
Regression of pre-existing intracerebral parental N32 glioma isografts induced by s.c. immunization with genetically altered N32 tumor cell clones Immunizations with N32 cells expressing IFN-␥ induced tumor regression and led to permanent survival (Ͼ200 days) in 100% of female rats (Fig 6A) and in 37% of males (Fig 6B) . The improvement of survival in both the male and female groups compared with N32-wt immunization was highly significant (P ϭ .002 and P Ͻ .0001, respectively). The first therapeutic dose was inoculated s.c. at 1 day after the intracerebral isografting of the N32-wt glioma. Three additional doses of s.c. immunization were administered with 2-week intervals.
Immunization with the N32-IL-7 clone led to permanent survival in 58% of female rats (Fig 6C) and in 17% of male rats (Fig 6D) . The survival of both females and males (immunized one to four times) was significantly improved (P ϭ .0325 and P ϭ .0002, respectively) compared with the combined survival of rats immunized with N32-wt from the N32-IFN-␥ and N32-B7-1 experiments.
Immunization with N32-B7-1 resulted in significantly improved survival compared with N32-wt immunization (P ϭ .005), with permanent (Ͼ150 days) survival of 88% female rats (Fig 6E) . None of the male rats showed a noticeably prolonged survival (Fig 6F) . For both males and females, all medium-immunized rats survived for Ͻ30 days. All rats were immunized four times within a 2-week interval.
Histopathological confirmation of the presence or absence of tumor at time of death
The presence or absence of an intracerebral tumor was confirmed in all animals killed because of neurological symptoms or at the end of the experiment by autopsy or histopathological examination. As shown in Figure 1 , three sections of the site of intracerebral tumor grafting were examined. An absence of tumor growth is demonstrated in a rat immunized with N32-IFN-␥ cells and killed at the end of the experiment (200 days after intracerebral challenge). In contrast, tumor outgrowth in N32-wt-immunized animals was extensive at 24 days after intracerebral challenge.
DISCUSSION
The present study demonstrates that a curative effect on pre-existing malignant gliomas growing intracerebrally can be induced by s.c. immunizations with cell clones of the same tumor transduced with the cytokines IFN-␥ and IL-7 or the costimulator B7-1. This finding indicates that the original tumor is quite sensitive to the immune response induced by certain genetically altered tumor cells; however, by itself, the original tumor is shown to have a very small capacity to induce this type of immune . IL-7 expression in a transfected clone selected for immunization in comparison with untransfected parental N32. The clone was tested directly after cloning (0 months) and was then frozen for later use; it was thawed on three occasions and retested after continuous culture and experimental usage for 3 months after thawing. The mean of these three determinations is indicated Ϯ SD. IL-7 expression was evaluated by a bioassay. Syngeneic thymocytes (5 ϫ 10 5 ) were stimulated by a suboptimal dose of Con A (0.6 g/mL) plus sample supernatants or IL-7 standard. After a 48-hour incubation at 37°C, the plates were incubated with [
3 H]thymidine for another 6 hours; cell incorporation was measured in a beta-counter.
response. This observation implies that although the original tumor expresses sufficient amounts of target peptides to be sensitive, it is deficient in providing or initiating the costimulatory signals necessary for the induction of a strong rejection response, which may be related in part to a failure to provide tumor peptide-MHC class I complexes in the concentrations required for the induction of a strong cytolytic response. This might make this response extremely dependent upon an efficient presentation of the tumor peptides on MHC class I of professional Ag-presenting cells or alternatively upon tumor cells with enhanced MHC class I expression. Consistent with this possibility are the results of a previous study, which demonstrated that admixing normal spleen cells enriched for dendritic cells to parental tumor cells augments the efficiency of parental tumor cells in therapeutic immunizations. 25 Important features of the present results are that they were achieved when the immunization was initiated after that the intracranial tumor had already been grafted and that they were not associated with any obvious neurological damage. Rat gliomas grow fast; with few exceptions, they have within 4 weeks reached a size in untreated controls that leads to neurological symptoms and to the death of the host. At the site of s.c. immunization, it takes ϳ1 week to reach a peak proliferative response in local lymph nodes and usually considerably longer before immune effector cells can be detected in the spleen as a sign of systemic immunity. 29, 30 The recorded effect of immunization on the growth of an intracerebral tumor requires that a sufficient number of effector cells pass the blood-brain barrier. This can be anticipated to take several days, which would allow the intracerebral parental tumor isograft to establish itself for several days before it can be affected by the induced immune effector cells. Locally, at the site of the intracranial tumor, the effector cells may be further stimulated to the extent that all tumor cells are being killed by the generated cytolytic effector cells. The number of tumor cells that were present at the intracerebral site at the time that the effector cells reached that location is unknown. Previous studies have demonstrated an infiltration of both CD4 ϩ and CD8 ϩ T cells in intracranial tumors after immunization with N32-derived, strongly immunogenic mutant tumor cell clones, † indicating that both subsets can penetrate the blood-brain barrier. The kinetics of this type of T-cell infiltration as a result of therapeutic immunization with the transfectants used in the present investigation needs to be analyzed.
We observed the strongest effect with the IFN-␥ transfectants. IFN-␥ is a pleiotrophic cytokine with a multitude of effects on immune mechanisms that might be relevant in the generation of cytolytic effector cells. In addition to its enhancing effect on MHC class I and II, as confirmed on the tumor cells used in the present study, IFN-␥ up-regulates heat shock protein glycoprotein 96 and the transporter proteins transporter associated with Ag processing 1 and 2 (which are important in peptide processing), IL-2, tumor necrosis factor, nitric oxide synthetase, and IFN-␥ itself. [31] [32] [33] [34] [35] [36] Besides being a key cytokine secreted by the T helper 1 (Th1) and T cytotoxic 1 (Tc1) cytotoxic clones supporting cytolytic immune responses, [37] [38] [39] it has also been suggested that IFN-␥ is able to initiate Th1 differentiation. 40 However, previously reported results in other tumor models have indicated variable effects, 11, 41, 42 which were mostly weaker than those of, for example, IL-2 or granulocytemacrophage colony-stimulating factor transfectants. 23, [43] [44] [45] [46] The inhibition of tumor growth achieved by immunization with cells expressing IL-7 was similar to that obtained by IFN-␥-expressing cells, although somewhat weaker. IL-7 may operate by preferentially stimulating the generation of CD8 ϩ CTLs. 47 Immunization with tumor cells expressing IFN-␥ and IL-7 induced cures in both male and female rats, but the cure frequency was higher in females. In contrast, although immunization with the B7-1 transfectant induced cures in females in as high a frequency as the other types of transfectants, it failed to do so in males. One explanation for the higher frequency of cures in females might be the well-known fact that female rodents have stronger cell-mediated immune responsiveness, making them more prone to autoimmune diseases and less susceptible to certain parasitic agents. 48, 49 Estrogen treatment and the castration of males can reverse their weaker reactivity. 50 Both male and female sexual hormones have regulating effects on the cytokine production of immune cells, and estrogen reportedly acts directly on the IFN-␥ promoter enhancing IFN-␥ production. [51] [52] [53] An alternative explanation may be that the tumor cells express male Ags, as the N32 tumor originates from a male rat, 26 and that the immune response to those Ags is added to that against tumor Ags. Although cell-mediated responses to male Ags have generally been found to be very weak, 54 they might possibly be of the same order of magnitude as the tumor Ags; therefore, we cannot exclude the possibility that this mechanism is involved in the sexual differences in tumor regression.
In the present investigation, we have tried to strengthen the immune rejection response sufficiently to overcome the possible immune suppression by factors such as TGF-␤ (which is often produced by gliomas), but we have made no attempt to specifically counteract the effect of this molecule. A different approach of considerable importance is to inhibit the TGF-␤ production of the tumor cells used for therapeutic immunization. 22 A combination of these two approaches should be most rewarding.
Although the immunization was initiated 1 day after the parental tumor was implanted intracerebrally, it realistically takes several days before any of the effector cells generated as a result of the immunization can reach the intracerebral tumor. Because the intracerebral tumor grows fast and kills the recipients within 3-4 weeks, the therapeutic immunizations cannot be delayed much in the present model. For further exploration of the therapeutic capacity of the present type of immunization against tumors that have established themselves for a longer period, one might have to slow down the tumor growth rate temporarily using some nonimmunological treatment. In this way, the effects of prolonged exposure to less rapidly growing tumor cells on the immune responsiveness against tumor Ags would be more analogous to the clinical situation.
In conclusion, the present results demonstrate that the intracerebral growth of a pre-existing wt brain tumor isograft can be totally or partially inhibited by s.c. immunizations with two types of genetically altered tumor cells initiated after the intracranial parental tumor grafting. No adverse neurological side effects were recorded in the immunized animals. In female rats, analogous results were obtained by immunization with tumor cells expressing the costimulator B7-1; however, no significant effect was recorded in males in this case, leaving the tumor specificity of the effect undetermined. The results form a solid basis for a detailed immunological analysis of the local and systemic immune responses and the types of tumor-infiltrating immune cells, which may correlate with cures and lack of cures, respectively. They also form an impetus to the further development of the tumor model to enable an analysis of the effect of similar therapeutic immunizations in rats that have been exposed to a progressively growing tumors for a longer period before the start of immunotherapy, an aspect that is even more clinically relevant. 
